Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...
Drug
Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA
Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National...
Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia
The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...
Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market
Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Akeso Biopharma Files New Indication for Penpulimab in First-Line NPC Treatment
Akeso Biopharma (HKG: 9926) has announced a new indication filing for its programmed death-1 (PD-1)...
Shanghai Junshi’s Loqtorzi Enters Australian Market Approval Process for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the Therapeutic Goods...
CARsgen Therapeutics Secures U.S. FDA Approval for CT071 Clinical Trials in Multiple Myeloma
CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received...
Lepu Biotechnology’s MRG003 Gains Fast-Track Status from U.S. FDA for Nasopharyngeal Carcinoma
Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced that its flagship product...
Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis
Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...
Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers
TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New...
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...
Simcere Secures NMPA Approval for Edaravone Sublingual Tablets Targeting Post-Stroke Cognitive Impairment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has received clinical trial approval from the National...
Everest Medicines Reports Positive Phase III Results for Velsipity in Ulcerative Colitis
Everest Medicines (HKG: 1952), based in China, has announced positive topline results from a multi-center...
AbbVie’s Telisotuzumab-Vedotin Shows Promising Results in NSCLC Phase 2 Trial
AbbVie (NYSE: ABBV) has unveiled data from a Phase 2 trial of its potential first-in-class...